Last reviewed · How we verify

A. Vogel AG — Portfolio Competitive Intelligence Brief

A. Vogel AG pipeline: 6 marketed, 0 filed, 5 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 5 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Echinaforce junior Echinaforce junior marketed Herbal immune stimulant Immunology / Infectious Disease
Echinaforce tincture Echinaforce tincture marketed
Echinaforce Chewable tablets Echinaforce Chewable tablets marketed Herbal immune stimulant Immunology / Infectious Disease
A. Vogels Sore Throat lozenges A. Vogels Sore Throat lozenges marketed Herbal remedy / Over-the-counter throat lozenge Otolaryngology / Symptomatic relief
Echinaforce Forte tablets Echinaforce Forte tablets marketed Herbal immunostimulant Immunology / Infectious Disease
Saw palmetto berry extract Saw palmetto berry extract marketed Herbal extract; 5-alpha reductase inhibitor 5-alpha reductase; androgen receptor (indirect) Urology
Nephrosolid tablets Nephrosolid tablets phase 3 Anti-inflammatory Nephrology
Echinaforce Echinaforce phase 3 Other
Eschscholzia tablets Eschscholzia tablets phase 3 Herbal extract / Natural anxiolytic Psychiatry / Sleep Medicine / Neurology
echinacea/sage echinacea/sage phase 3 Infectious Diseases
chlorhexidine/lidocaine chlorhexidine/lidocaine phase 3 Topical antiseptic and local anesthetic Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bausch & Lomb Incorporated · 1 shared drug class
  2. Marie Hudson, MD · 1 shared drug class
  3. Organon and Co · 1 shared drug class
  4. Panacea Biotec Ltd · 1 shared drug class
  5. Prof. Dr. Stephan Weidinger · 1 shared drug class
  6. Salus Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for A. Vogel AG:

Cite this brief

Drug Landscape (2026). A. Vogel AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/a-vogel-ag. Accessed 2026-05-14.

Related